Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-30
2011-08-30
Li, Bao (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S229100, C424S093100
Reexamination Certificate
active
08008265
ABSTRACT:
Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes an immunomodulator protein selected from the group consisting of: Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, IkB, Inactive NIK, SAP K, SAP-1, JNK, interferon response genes, NFkB, Bax, TRAIL, TRAILrec, TRAILrecDRC5, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, Ox40, Ox40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAP1, TAP2 and functional fragments thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
REFERENCES:
patent: 4722848 (1988-02-01), Paoletti et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 5017487 (1991-05-01), Stunnenberg et al.
patent: 5036006 (1991-07-01), Sanford et al.
patent: 5077044 (1991-12-01), Stocker
patent: 5110587 (1992-05-01), Paoletti et al.
patent: 5112749 (1992-05-01), Brey
patent: 5174993 (1992-12-01), Paoletti
patent: 5223424 (1993-06-01), Cochran
patent: 5225336 (1993-07-01), Paoletti
patent: 5240703 (1993-08-01), Cochran
patent: 5242829 (1993-09-01), Panicali
patent: 5294441 (1994-03-01), Curtiss
patent: 5294548 (1994-03-01), McIinden
patent: 5310668 (1994-05-01), Ellis
patent: 5387744 (1995-02-01), Curtiss
patent: 5389368 (1995-02-01), Curtiss
patent: 5424065 (1995-06-01), Curtiss
patent: 5451499 (1995-09-01), Cochran
patent: 5453364 (1995-09-01), Paoletti
patent: 5462734 (1995-10-01), Letchworth
patent: 5470734 (1995-11-01), Sondermeijer
patent: 5482713 (1996-01-01), Paoletti
patent: 5580859 (1996-12-01), Felgner
patent: 5593972 (1997-01-01), Weiner
patent: 5676594 (1997-10-01), Joosten
patent: 5703055 (1997-12-01), Felgner
patent: 5739118 (1998-04-01), Carrano
patent: 5817634 (1998-10-01), Meezan
patent: 5830876 (1998-11-01), Weiner
patent: 5962425 (1999-10-01), Walder
patent: 5981505 (1999-11-01), Weiner
patent: 6017735 (2000-01-01), O'Hare et al.
patent: 6344445 (2002-02-01), Boursnell et al.
patent: 2002/0044941 (2002-04-01), Rosen et al.
patent: 2003/0113919 (2003-06-01), Emtage et al.
patent: 2002-504334 (2002-02-01), None
patent: WO 94/16737 (1994-08-01), None
patent: WO 98/44129 (1998-10-01), None
patent: WO 99/42585 (1999-08-01), None
patent: WO 02/100345 (2002-12-01), None
Kruse et al. Proc. Natl. Acad. Sci. USA, 1997, vol. 94, pp. 12396-12400.
Kerppola et al. EMBO J. 1997, vol. 16 (10), pp. 2907-2916.
Zhan et al. DNA and Cell Biology, 2000, vol. 19, No. 11, pp. 637-645.
Taylor et al. J. Leukocyte Biology Sep. 2002, vol. 72, pp. 522-529.
Song et al. Mol Biol Cell. Mar. 2004; 15(3): 1287-1296.
Hodge et al. .JNCI 2000, vol. 92, No. 15, pp. 1228-1239.
Hinuma et al. FEBS 1991, vol. 288, No. 1-2, pp. 138-142.
Wiethe, C et al., “Enhanced Effector and Memory CTL Responses Generated by Incorporation of Receptor Activator of NF-k (RANK)/RANK Ligand Costimulatory Molecules into Dendritic Cell Immunogens Expressing a Human Tumor-Specific Antigen,” The Journal of Immunology (2003) 171(8):4121-30.
Hurwitz, A. et al., “Costimulatory wars: the tumor menace,” Current Opinion in Immunology (2000) 12(5):589-596.
Wiethe, C. et al., “Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen”, Journal of Immunology, 2003, 170 (6):2912-2922.
Zheng, J. et al., “Enhanced immune response to DNA-based HPV16L1 vaccination by costimulatory molecule B7-2”, Antiviral Research, 2003:59(1):61-65.
Chaudhary, V.K., et al., “A rapid method of cloning functional variable-region antibody genes inEscherichia colias single-chain immunotoxins,” Proc. Natl. Acad Sci. USA(1990) 87(3):1066-70.
Chiu et al., “The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes,”Cell(1988) 54(2):541-552.
Durkop, H et al., “Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease,”Cell(1992) 68(3),421-427.
Franklin et al., “Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells,”Oncogene(1995) 11(11):2365-74.
Gilmore et al., “The I kappa B proteins: members of a multifunctional family,”Trens Genet(1993) 9(12):427-33.
Howell, M.D., et al., “Limited T-cell receptor beta-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis.,”Proc. Nat. Acad. Sci USA. (1991) 88:10921-10925.
Lee et al., “Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements,”Cell(1987) 49(6):741-752.
Meyer R., et al., “Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha.,”Proc. Natl. Acad. Sci USA(1991) 88(3),966-970.
Oksenberg, J.R., et al., “Limited heterogeneity of rearranged T-cell receptor Vα transcripts in brains of multiple sclerosis patients, ”Nature(1990) 345(6264):344-346.
Paliard, X., et al., “Evidence for the effects of a superantigen in rheumatoid arthritis., ”Science(1991) 253(5017):325-329.
Rauscher et al., “Fos-associated protein p39 is the product of the jun proto-oncogene,”Science(1988) 240(4855):1010-1016.
Smith, C.A., et al., “CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF,”Cell(1993) 73(7):1349-1360.
Williams, W.V., et al., “Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium.,”J Clin. Invest. (1992) 90(2):326-333.
Wucherpfennig, K.W., et al., “Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein.,”Science(1990) 248(4958):1016-1019.
Murakami, M. “High-level expression of exogenous genes by replication-competent retrovirus vectors with an internal ribosomal entry site.”Gene(1997) 202:23-29.
Clement, A. et al., Prime-boost immunization with DNA and modified vaccine virus Ankara vector expressing herpes simplex virus-2 glycoprotein d elicits create specific antibody and cytokine responses than DNA vaccine alone, J. Infectious Dis. 2001, vol. 186. pp. 1065-1073.
Luo, Y. et al., “Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine.”PNAS(2003) 100; 8850-8855.
Stuber, E. et al., “Cross -Linking of OX40 Ligand, a Member of the TNF/NGF Cytokine Family, Induces Proliferation and Differentiation in Murine Splenic B Cells”, Immunity, 1995, 2:507-521.
Chattergoon Michael A.
Choo Andrew Y.
Kutzler Michele
Muthumani Karuppiah
Weiner David B.
Li Bao
Pepper Hamilton LLP
The Trustees of the University of Pennsylvania
LandOfFree
Vaccines, immunotherapeutics and methods for using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccines, immunotherapeutics and methods for using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines, immunotherapeutics and methods for using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2776751